TARGET THERAPY FOR NON-SMALL CELL LUNG CANCER: COMPLETE RESPONSE TO CRIZOTINIB
Olga O. Gordeeva , A. A Meshcheryakov , N. A Meshcheryakova
Russian Journal of Oncology ›› 2019, Vol. 24 ›› Issue (1-2) : 27 -31.
TARGET THERAPY FOR NON-SMALL CELL LUNG CANCER: COMPLETE RESPONSE TO CRIZOTINIB
In this article we demonstrate a clinical case of young patient with non-small lung cancer with ALK-translocation treated with crizotinib in the first line of therapy. This approach was associated with complete response and acceptable toxicity.
ALK / non-small cell lung cancer / ALK / targeted therapy / crizotinib
| [1] |
Arteaga C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol. 2002; 29: 3-9. |
| [2] |
Paez J.G., Janne P.A., Lee J.C. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (Wash D C). 2004; 304: 1497-500 |
| [3] |
Soda M., Choi Y.L., Enomoto M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448 (7153): 561-6. |
| [4] |
Alice T. Shaw, Beow Y. Yeap, Mari Mino-Kenudson, et al. Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK. J Clin. Oncol. 27: 4 247-53. |
| [5] |
Ming Sound Tsao, Fred R. Hirsch, Yasushi Yatabe. IASLC atlas of ALK testing in lung cancer. 2013. |
| [6] |
Benjamin J. Solomon et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. N. Engl. J. Med. 2014; 371: 2167-77. |
| [7] |
Юкальчук Д.Ю. и др. Применение кризотиниба в терапии ALK-позитивного немелкоклеточного рака лёгкого. Эффективная фармакотерапия. Онкология, гематология и радиология. Спецвыпуск «Рак: расширяя возможности лечения». 2016; 8. |
| [8] |
Paik P.K., Drilon A., Fan P.D. et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015; 5: 842-9. |
Eco-Vector
/
| 〈 |
|
〉 |
PDF
